 LEXINGTON, Mass., May 3, 2021 PRNewswire -- LogicBio Therapeutics, Inc. Nasdaq:LOGC, a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced results from a retrospective study of the disease course in pediatric patients living with severe methylmalonic acidemia MMA caused by a deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase MMUT. 